Antimicrobial resistance following azithromycin mass drug administration: potential surveillance strategies to assess public health impact Ines Mack1, Mike Sharland2, James A Berkley3,4, Nigel Klein5, Surbhi MalhotraKumar6, Julia Bielicki1,2 1 Paediatric Infectious Diseases, University Children’s Hospital Basel, Basel, Switzerland 2 Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, UK 3 Center for Tropical Medicine and Global Health, University of Oxford, Oxford, UK 4 KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya 5 UCL Great Ormond Street Institute of Child Health, London, UK 6 Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, Universiteit Antwerpen, Antwerp, Belgium Key words: Macrolide; azithromycin; mass drug administration; antimicrobial resistance; surveillance; Running title: AMR surveillance after azithromycin MDA Article’s main points Azithromycin Mass Drug Administration results in a sustained increase in antimicrobial resistance when implemented at a population level. Targeted risk-based metagenomics approaches complementing traditional microbiological methods are recommended for surveillance of emerging short- and long-term antimicrobial resistance. 1 Corresponding author: Ines Mack | Spitalstr. 33 | 4056 Basel | Switzerland | [email protected] | Phone 0041 61 704 22 37 | Fax 0041 61 704 12 53 Alternate corresponding author: Julia Bielicki | Spitalstr. 33 | CH-4056 Basel | Switzerland | [email protected] | Phone 0041 61 704 28 58 | Fax 0041 61 704 12 53 2 ABSTRACT The reduction of childhood mortality noted in trials investigating azithromycin mass drug administration (MDA) for trachoma control has been confirmed by a recent large randomised controlled trial. Population-level implementation of azithromycin MDA may lead to selection of multi-resistant pathogens. Evidence suggests that repeated azithromycin MDA may result in a sustained increase in macrolide and other antibiotic resistance in gut and respiratory bacteria. Current evidence comes from standard microbiological techniques in studies focused on a time-limited intervention, while MDA implemented for mortality benefits would likely repeatedly expose the population over a prolonged period and may require a different surveillance approach. Targeted short-term and long-term surveillance of resistance emergence to key antibiotics, especially those from the WHO Access group, is needed throughout any implementation of azithromycin MDA, focusing on a genotypic approach to overcome the limitations of resistance surveillance in indicator bacteria. 3 DISCUSSION Intermittent childhood azithromycin mass drug administration in sub-Saharan Africa: current indications and supporting evidence The most frequent indication for azithromycin mass drug administration (AZM MDA) across Africa is endemic trachoma [1]. In 1997, the WHO established the Global Alliance for the Elimination of Blinding Trachoma by 2020 (GET 2020), and there is clear evidence that single-dose AZM MDA reduces the prevalence of active trachoma and ocular infection [2]. A reduction in childhood mortality was observed in studies of AZM MDA for trachoma in the sub-Saharan setting [3 ,[4]. The MORDOR I study (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance, clinicaltrials.gov # NCT02048007) [4] was specifically designed to investigate any potential mortality benefit. The study assigned communities in Malawi, Niger and Tanzania to four twice-yearly MDA rounds of either 20 mg/kg per dose oral AZM or placebo. This cluster randomized controlled trial demonstrated a reduction of allcause mortality in under-five year old children of 14% in the treatment group [4]. Mortality reduction (18%) was observed most clearly among infants in Niger and those who were less than 6 months of age with the highest mortality rate at baseline. Extension for two more rounds during MORDOR II did not show significant evidence of a waning effect of AZM MDA on childhood mortality [5]. In communities who received placebo originally, childhood mortality decreased after receipt of AZM [5]. Emergence of antibiotic resistance linked to antibiotic MDA could be a barrier to widespread implementation. There are concerns that AZM MDA will lead to selection of macrolide-resistant strains of Chlamydia trachomatis, and resistance to macrolides and other classes of antimicrobials in ot

docxDoc Antimicrobial Resistance Following Azithromycin Mass Drug Administration Potential Surveillance Strategies to Assess Public Health Impact

Practical Docs > Common > Other > Preview
22 Pages 0 Downloads 27 Views 3.0 Score
Tips: Current document can only be previewed at most page3,If the total number of pages in the document exceeds page 3,please download the document。
Uploaded by admin on 2022-04-23 01:57:58
Rate
You can enter 255 characters
What is my domain?( answer:www.45doc.com )
comments
  • No comments yet